… Focal therapy (FT) for prostate cancer (PCa) seems to be part of a natural evolution in the
quest to … Focal therapy (FT) has emerged as a middle ground between AS and radical therapy, …

… The hallmark feature of focal therapy is the targeted focal destruction of cancer tissue with …
provided by focal therapies for prostate cancer aims to infer a favourable morbidity profile, with …

… >0.5 ng/ml), and no correlation currently exists between post-HIFU PSA outcomes and more
meaningful end points such as secondary therapy, metastases, or cancer-specific mortality. …

… , (2) disease localisation, (3) identification of which lesions to target, (4) definitions of
success and failure in focal therapy, and (5) morbidity and cancer-control outcomes after …

… , many clinicians still believe that we are overtreating prostate cancer and creating
unnecessary morbidity. For example, the ERSPC indicates that we need to treat 48 men (…

… irrespective of the volume or number of cancers in the prostate. In … of prostate cancer focality
in the context of focal treatment. … morbidity rates than whole-gland therapy; however, data on …

… Most series are relatively immature, with a lack of consistent follow-up, and the morbidity
of retreatment is often not considered. The authors consider focal therapy to be an …

… of focal destruction of prostate tissue with minimal morbidity. We encourage the investigation
of focal therapy in select men with low risk prostate cancer in … outcomes and cancer control. …

… data on focal therapy (FT) when used alone as definitive therapy for primary prostate cancer
(… to perform a meta-analysis for BPFS, cancer-specific patient mortality and overall mortality. …

… treatment) and patients who may be managed more conservatively, such as through active
surveillance or emerging focal therapy (FT). … Treatment-related morbidity in prostate cancer: a …